Membrane proteomic profiling to identify candidate therapy targets for glioblastoma infiltration

ABSTRACT: Isocitrate dehydrogenase wild type glioblastoma (GBM) is an aggressive brain tumour characterized by rapid growth and infiltration into adjacent functional brain tissue. Presently, treatment is restricted to surgical resection followed by temozolomide chemotherapy and concomitant radiotherapy; however, new therapies are desperately needed to improve GBM patient outcome. Intra-tumoural heterogeneity is a common driver of failure for novel GBM treatments, and many preclinical studies rely on cell lines established from the tumour core. As a result, they fail to characterise the infiltrative cells which remain post-surgery and ultimately drive tumour recurrence. This study characterises the membrane proteome of 3 patient-derived GBM cell lines isolated from the tumour infiltrative margin (GIN8, GIN28, and GIN31), which are a proxy for residual disease post-surgery.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Astrocyte

DISEASE(S): Brain Glioblastoma Multiforme

SUBMITTER: David Boocock  

LAB HEAD: David John Boocock

PROVIDER: PXD058999 | Pride | 2026-09-07

REPOSITORIES: Pride